A Phase 1 Study in Healthy Subjects to Evaluate the Relative Bioavailability of ABBV-154
Latest Information Update: 15 Mar 2023
Price :
$35 *
At a glance
- Drugs ABBV-154 (Primary)
- Indications Inflammation
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 09 Mar 2023 Status changed from active, no longer recruiting to completed.
- 14 Dec 2022 Status changed from recruiting to active, no longer recruiting.
- 21 Oct 2022 Status changed from not yet recruiting to recruiting.